To the 100th anniversary of the birth of academician V.A. Nasonova. Osteoporosis: Yesterday, today, tomorrow
https://doi.org/10.47360/1995-4484-2023-249-259
Abstract
Osteoporosis (OP) is the most common bone disorder associated with an increase bone fragility and a high fracture risk, which can be an isolated condition or a comorbidity of immuno-inflammatory rheumatic diseases. A great contribution to the study of OP in the Russian Federation was made by V.A. Nasonova, L.I. Benevolenskaya and scientific researchers of the Institute of Rheumatology. The article presents the main achievements that have occurred over the past 30 years in the development of this problem in our country and abroad, and the perspectives of osteoporosis treatment.
About the Authors
N. V. Toroptsova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
O. A. Nikitinskaya
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology;
I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A;
119991, Moscow, Trubetskaya str., 8, building 2
References
1. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137-1141. doi: 10.1002/jbmr.5650090802
2. Benevolenskaya LI, Nasonov EL. The pathogenesis of osteoporosis. Rukovodstvo po osteoporozu. M.:BINOM. Laboratoriya znaniy;2003:77-104 (In Russ.).
3. Mikhailov EE, Benevolenskaya LI. Epidemiology of osteoporosis and fractures. Rukovodstvo po osteoporozu. M.:BINOM. Laboratoriya znaniy;2003:10-53 (In Russ.).
4. Lesnyak OM, Baranova IA, Belova KY, Gladkova EN, Evstigneeva LP, Ershova OB, et al. Osteoporosis in Russian Federation: Epidemiology, sociomedical and economical aspects (review). Traumatology and Orthopedics of Russia. 2018;24(1):155-168 (In Russ.). doi: 10.21823/2311-2905-2018-24-1-155-168
5. Lunt M, Felsenberg D, Adams J, Benevolenskaya L, Cannata J, Dequeker J, et al. Population-based geographic variations in DXA bone density in Europe: The EVOS Study. European Vertebral Osteoporosis. Osteoporos Int. 1997;7(3):175-189. doi: 10.1007/BF01622286
6. O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ. The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study. J Bone Miner Res. 1996;11(7):1010-1018. doi: 10.1002/jbmr.5650110719
7. European Prospective Osteoporosis Study (EPOS) Group; Felsenberg D, Silman AJ, Lunt M, Armbrecht G, Ismail AA, et al. Incidence of vertebral fracture in Europe: Results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res. 2002;17(4):716-724. doi: 10.1359/jbmr.2002.17.4.716
8. Lesnyak O, Ershova O, Belova K, Gladkova E, Sinitsina O, Ganert O, et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos. 2012;7:67-73. doi: 10.1007/s11657-012-0082-3
9. Toroptsova NV, Nikitinskaya OA, Benevolenskaya LI. Primary osteoporosis prophylaxis with different calcium preparations. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2005;43(1):36-39 (In Russ.). doi: 10.14412/1995-4484-2005-554
10. Toroptsova NV, Nikitinskaya OA, Benevolenskaya LI, Toroptsova NV, Nikitinskaya OA, Benevolenskaya LI. New view of the prevention of osteoporosis: focus on Calcium-D3 Nycomed. Modern Rheumatology Journal. 2007;1(1):64-68 (In Russ.). doi: 10.14412/1996-7012-2007-445
11. Myakotkin VA, Krylov MY, Kaseeva AY, Maslova KA, Toroptsova NK, Nikitinskaya OA, et al. Assessment of genes LRP5, BVP4, TGFβl polymorphisms significance in postmenopausal osteoporosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2008;46(3):8-15 (In Russ.). doi: 10.14412/1995-4484-2008-653
12. Maslova KA, Krylov MY, Toroptsova NV, Nikitinskaya OA, Korotkova TA, Myakotkin VA, et al. Estrogenic receptors α and β gene polymorphisms in postmenopausal osteoporosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2008;46(3):16-22 (In Russ.). doi: 10.14412/1995-4484-2008-654
13. Myakotkin VA, Krylov MYu, Guseva IA, Chetina EV, Toroptsova NV, Nikitinskaya OA, et al. Molecular genetic testing of osteoporosis susceptibility in postmenopausal women in Moscow. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2011;49(2):15-20 (In Russ.). doi: 10.14412/1995-4484-2011-597
14. Krylov MYu, Nikitinskaya OA, Samarkina EYu, Demin NV, Toroptsova NV. Farnesyl diphosphate synthase (FDRS) and geranylgeranyl diphosphate synthase (GGSP1) gene polymorphisms and efficiency of therapy with bisphosphonates in Russian women with postmenopausal osteoporosis: A pilot study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(1):49-52 (In Russ.) doi: 10.14412/1995-4484-2016-49-52
15. Krylov MYu, Nikitinskaya OA, Samarkina EYu, Toroptsova NV. Strontium ranelate in the treatment of postmenopausal osteoporosis: Impact of vitamin D receptor and monocyte chemoattractant protein-1 gene polymorphisms on bone mineral density: A pilot study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(3):267-271 (In Russ.). doi: 10.14412/1995-4484-2017-267-271
16. Nikitinskaya OA, Toroptsova NV. Osteoporosis and osteoporotic fractures risk factors in men aged 50 years and older. Osteoporosis and Bone Diseases. 2017;20(1):7-11 (In Russ.). doi: 10.14341/osteo201717-11
17. Nikitinskaya OA, Toroptsova NV. Assessment of 10-year probability of osteoporotic fractures with the Russian model of FRAX® in a population-based sample 5 regions of Russia. Medical Council. 2017;(1S):103-107 (In Russ.). doi: 10.21518/2079-701X-2017-0-103-107
18. Nikitinskaya OA, Toroptsova NV, Demin NV. Risk factors and bone mineral density in predicting the risk of fracture in postmenopausal women. Modern Rheumatology Journal. 2016;10(3):23-28 (In Russ.). doi: 10.14412/1996-7012-2016-3-23-28
19. Nikitinskaya OA, Toroptsova NV. Assessment of fractures risk using the FRAX® tool (a ten-year retrospective study). Almanac of Clinical Medicine. 2014;32:50-55 (In Russ.). doi: 10.18786/2072-0505-2014-32-50-55
20. Nikitinskaya OA, Toroptsova NV. Progress of osteoporosis: Stratification of fracture risk. Osteoporosis and Bone Diseases. 2018;21(1):4-9 (In Russ.). doi: 10.14341/osteo9620
21. Dobrovolskaya OV, Toroptsova NV. Postmenopausal osteoporosis: Quality of life of patients after fractures. Effective Pharmacotherapy. 2015;46:8-13 (In Russ.).
22. Svedbom A, Borgstöm F, Hernlund E, Ström O, Alekna V, Bianchi ML, et al. Quality of life for up to 18 months after lowenergy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int. 2018;29(3):557-566. doi: 10.1007/s00198-017-4317-4
23. Lesnyak O, Svedbom A, Belova K, Dobrovolskaya O, Ershova O, Golubev G, et al. Quality of life after fragility fracture in the Russian Federation: Results from the Russian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (ICUROS). Arch Osteoporos. 2020;15(1):37. doi: 10.1007/s11657-020-0699-6
24. Dobrovolskaya OV, Toroptsova NV, Lesnyak OM. Economic aspects of complicated osteoporosis: The cost of treatment in the first year after fracture. Modern Rheumatology Journal. 2016;10(3):29-34 (In Russ.). doi: 10.14412/1996-7012-2016-3-29-34
25. Toroptsova NV. Clinical experience with alendronate for the treatment of osteoporosis. Effective Pharmacotherapy. 2009;6:6-11 (In Russ.).
26. Toroptsova NV, Benevolenskaya LI. Results of the use of zoledronic acid in the treatment of osteoporosis. Osteoporosis and Bone Diseases. 2008;11(2):25-28 (In Russ.). doi: 10.14341/osteo2008225-28
27. Rozhinskaya LA, Arapova SD, Dzeranova LK, Molitvoslovova NN, Marova EI, Shishkina AA, et al. Results of a Russian multicenter study of the efficacy and tolerability of bivalos (strontium ranelate) in women with postmenopausal osteoporosis. Osteoporosis and Bone Diseases. 2007;10(3):24-30 (In Russ.). doi: 10.14341/osteo2007324-30
28. Rozhinskaya LA, Arapova SD, Dzeranova LK, Molitvoslovova NN, Ilyin AV, Sazonova NI, et al. Efficacy and safety study of teriparatide (forsteo) therapy for 1 year in postmenopausal osteoporosis. Osteoporosis and Bone Diseases. 2006;9(2):6-12 (In Russ.). doi: 10.14341/osteo200626-12
29. Ershova OB, Lesniak OM, Belova KI, Nazarova AV, Manovitskaia AV, Musaeva TM, et al. Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis. Terapevticheskii arkhiv. 2014;86(10):60-64 (In Russ.).
30. Nikitinskaya OA, Toroptsova NV, Feklistov AY, Demin NV, Abramkin AA. Treatment of patients with osteoporosis in modern clinical practice: Adherence to therapy. Osteoporosis and Bone Diseases. 2015;18(1):23-27 (In Russ.). doi: 10.14341/osteo2015123-27
31. Dobrovolskaya OV, Toroptsova NV, Nikitinskaya OA, Demin NV. Treatment of osteoporosis in real clinical practice: Frequency of prescriptions and therapy adherence within the first year after osteoporotic fracture. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2011;49(5):24-27 (In Russ.). doi: 10.14412/1995-4484-2011-1456
32. Nikitinskaya OA, Toroptsova NV, Nasonov EL. Osteoporosis treatment adherence: Results from a retrospective cohort study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):415-420 (In Russ.). doi: 10.14412/1995-4484-2019-415-420
33. Nasonov EL (ed.). Rheumatology: Russian clinical guidelines. Moscow:GEOTARMedia;2017 (In Russ.).
34. Adami G, Fassio A, Rossini M, Caimmi C, Giollo A, Orsolini G, et al. Osteoporosis in Rheumatic Diseases. Int J Mol Sci. 2019;20(23):5867. doi: 10.3390/ijms20235867
35. Rossini M, Gatti D, Adami S. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93(2):121-132. doi: 10.1007/s00223-013-9749-z
36. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156-163. doi: 10.1038/nm1538
37. Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C, et al. In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol. 2015;33(1):77-83.
38. Ma Y, Zhang X, Wang M, Xia Q, Yang J, Wu M, et al. The serum level of Dickkopf-1 in patients with rheumatoid arthritis: A systematic review and meta-analysis. Int Immunopharmacol. 2018;59:227-232. doi: 10.1016/j.intimp.2018.04.019
39. Rossini M, Viapiana O, Idolazzi L, Ghellere F, Fracassi E, Troplini S, et al. Higher level of Dickkopf-1 is associated with low bone mineral density and higher prevalence of vertebral fractures in patients with ankylosing spondylitis. Calcif Tissue Int. 2016;98(5):438-445. doi: 10.1007/s00223-015-0093-3
40. Hauser B, Harre U. The role of autoantibodies in bone metabolism and bone loss. Calcif Tissue Int. 2018;102(5):522-532. doi: 10.1007/s00223-017-0370-4
41. Orsolini G, Caimmi C, Viapiana O, Idolazzi L, Fracassi E, Gatti D, et al. Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients. Calcif Tissue Int. 2017;101(1):17-23. doi: 10.1007/s00223-017-0253-8
42. Llorente I, Merino L, Ortiz AM, Escolano E, González-Ortega S, García-Vicuña R, et al. Anti-citrullinated protein antibodies are associated with decreased bone mineral density: Baseline data from a register of early arthritis patients. Rheumatol Int. 2017;37(5):799-806. doi: 10.1007/s00296-017-3674-9
43. Bugatti S, Bogliolo L, Vitolo B, Manzo A, Montecucco C, Caporali R. Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):226. doi: 10.1186/s13075-016-1116-9
44. Hauser B, Riches PL, Gilchrist T, Visconti MR, Wilson JF, Ralston SH. Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Ann Rheum Dis. 2015;74(8):1631-1632. doi: 10.1136/annrheumdis-2014-207219
45. Hauser B, Zhao S, Visconti MR, Riches PL, Fraser WD, Piec I, et al. Autoantibodies to osteoprotegerin are associated with low hip bone mineral density and history of fractures in axial spondyloarthritis: A cross-sectional observational study. Calcif Tissue Int. 2017;101(4):375-383. doi: 10.1007/s00223-017-0291-2
46. Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14(2):106-112. doi: 10.1191/0961203305lu2039oa
47. Nasonov EL, Skripnikova IA, Nasonova VA. The problem of osteoporosis in rheumatology. Moscow:STIN;1997 (In Russ.).
48. Taskina EA, Alekseeva LI, Dydykina IS, Podvorotova MM, Dydykina PS, Petrova EV, et al. Risk factors for osteoporosis in patients with rheumatoid arthritis (preliminary results according to the materials of the multicenter program «osteoporosis in rheumatoid arthritis: Diagnosis, risk factors, fractures, treatment»). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(4):393-397 (In Russ.). doi: 10.14412/1995-4484-2014-393-397
49. Taskina EA, Alekseeva LI, Dydykina IS. Factors in the development of osteoporosis in women with a preserved menstrual cycle suffering from rheumatoid arthritis. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice: Abstracts of the VII Congress of Rheumatologists. 2017;55(1S):125 (In Russ.).
50. Podvorotova MM, Dydykina IS, Taskina EA, Raskina TA, Koroleva MA, Muradyants AA, et al. Risk factors for fractures in patients with rheumatoid arthritis (preliminary results of the multicenter program «Osteoporosis in rheumatoid arthritis: Diagnosis, risk factors, fractures, treatment»). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2013;51(2):154-158. (In Russ.) doi: 10.14412/1995-4484-2013-643
51. Gavva TN, Popkova TV, Smirnov AV, Mach ES, Novikova DS, Alexandrova EN, et al. Relationship between C-reactive protein concentration, bone mineral density and cardiovascular disturbances in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2008;46(3):30-38 (In Russ.). doi: 10.14412/1995-4484-2008-656
52. Dobrovolskaya OV, Kovalenko PS, Toroptsova NV, Dydykina IS, Nikitinskaya OA, Nasonov EL. Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: Results of 1-year study in clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(2):160-165 (In Russ.). doi: 10.14412/1995-4484-2019-160-165
53. Kovalenko PS, Dydykina IS, Smirnov AV, Nasonov EL. Bone resorption during therapy with denosumab in patients with rheumatoid arthritis, positive for the main immunological markers. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(5):573-579 (In Russ.). doi: 10.47360/1995-4484-2022-573-579
54. Dydykina PS, Petrova ЕV, Dydykina IS, Smirnov AV, Glukhova SV, Alekseeva LI, et al. Effect of denosumab on clinical and radiological changes in rheumatoid arthritis. Preliminary results. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(2):134-138 (In Russ.). doi: 10.14412/1995-4484-2015-134-138
55. Efremova AО, Toroptsova NV, Dobrovolskaya OV, Demin NV, Nikitinskaya OA. The risk of fractures and the need for anti-osteoporotic treatment in patients with systemic sclerosis. Modern Rheumatology Journal. 2021;15(1):32-37 (In Russ.). doi: 10.14412/1996-7012-2021-1-32-37
56. Efremova AO, Toroptsova NV, Dobrovolskaya OV, Starovoitova MN, Desinova OV, Nikitinskaya OA. Risk factors for low bone mineral density in postmenopausal women with systemic sclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(5):592-598 (In Russ.). doi: 10.47360/1995-4484-2021-592-598
57. Sorokina AO, Demin NV, Dobrovolskaya OV, Nikitinskaya OA, Toroptsova NV, Feklistov AYu. Pathological phenotypes of body composition in patients with rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):487-494 (In Russ.). doi: 10.47360/1995-4484-2022-487-494
58. Dobrovolskaya OV, Demin NV, Baranova MM, Shebzukhova DM, Feklistov AYu, Toroptsova NV. Frequency of osteoporosis and sarcopenia in patients with osteoarthritis. Botkinskie chteniya: Sbornik tezisov Vserossiyskogo terapevticheskogo kongressa s mezhdunarodnym uchastiem. Мoscow:2020:86-87 (In Russ.).
59. Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019;170(1):ITC1-ITC16. doi: 10.7326/AITC201901010
60. Szentpétery Á, Horváth Á, Gulyás K, Pethö Z, Bhattoa HP, Szántó S, et al. Effects of targeted therapies on the bone in arthritides. Autoimmun Rev. 2017;16(3):313-320. doi: 10.1016/j.autrev.2017.01.014
61. Soós B, Szentpétery Á, Raterman HG, Lems WF, Bhattoa HP, Szekanecz Z. Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2022;18(5):249-257. doi: 10.1038/s41584-022-00764-w
62. Shao F, Li HC, Wang MJ, Cui CM. Impact of biologic diseasemodifying antirheumatic drugs on fracture risk in patients with rheumatoid arthritis: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(9):3416-3424. doi: 10.26355/eurrev_202105_25821
63. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62(1):33-43. doi: 10.1002/art.25053
64. Abu-Shakra M, Zisman D, Balbir-Gurman A, Amital H, Levy Y, Langevitz P, et al. Effect of tocilizumab on fatigue and bone mineral density in patients with rheumatoid arthritis. Isr Med Assoc J. 2018;20(4):239-244.
65. Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, Chao WC, et al. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. PLoS One. 2017;12(11):e0188454. doi: 10.1371/journal.pone.0188454
66. Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T. Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study. Rheumatol Int. 2018;38(5):777-784. doi: 10.1007/s00296-017-3922-z
67. Wheater G, Elshahaly M, Naraghi K, Tuck SP, Datta HK, van Laar JM. Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study. PLoS One. 2018;13(8):e0201527. doi: 10.1371/journal.pone.0201527
68. Demin NV, Kusevich DA, Dobrovolskaya OV. BMD status in women with rheumatoid arthritis after one year of rituximab therapy. Osteoporosis and Bone Diseases. 2022;25(3):41-41 (In Russ.). doi: 10.14341/osteo13006
69. Al Khayyat SG, Falsetti P, Conticini E, D’Alessandro R, Bellisai F, Gentileschi S, et al. Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis – retrospective study. Reumatologia. 2021;59(4):206-210. doi: 10.5114/reum.2021.108430
70. Raskina TA, Koroleva MV, Malyshenko OS. Changes of bone mineral density during four-year rituximab and methotrexate therapy in postmenopausal women with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(5):530-534 (In Russ.). doi: 10.14412/1995-4484-2016-530-534
71. Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10(10):CD001347. doi: 10.1002/14651858.CD001347.pub2
72. Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int. 2014;25(12):2755-2765. doi: 10.1007/s00198-014-2819-x
73. Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, et al. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone. 2018;116:58-66. doi: 10.1016/j.bone.2018.07.013
74. Suzuki T, Nakamura Y, Kato H. Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis. Ther Clin Risk Manag. 2018;14:453-459. doi: 10.2147/TCRM.S156350
75. Hasegawa T, Kaneko Y, Izumi K, Takeuchi T. Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis. Joint Bone Spine. 2017;84(3):379-380. doi: 10.1016/j.jbspin.2016.05.010
76. Lau AN, Wong-Pack M, Rodjanapiches R, Ioannidis G, Wade S, Spangler L, et al. Occurrence of serious infection in patients with rheumatoid arthritis treated with biologics and denosumab observed in a clinical setting. J Rheumatol. 2018;45(2):170-176. doi: 10.3899/jrheum.161270
77. Kobayakawa T, Miyazaki A, Kanayama Y, Hirano Y, Takahashi J, Suzuki T, et al. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol. 2023;33(1):96-103. doi: 10.1093/mr/roac014
78. Song S, Guo Y, Yang Y, Fu D. Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol Ther. 2022;237:108168. doi: 10.1016/j.pharmthera.2022.108168
79. Zhao Y, Shao G, Liu X, Li Z. Assessment of the therapeutic potential of melatonin for the treatment of osteoporosis through a narrative review of its signaling and preclinical and clinical studies. Front Pharmacol. 2022;13:866625. doi: 10.3389/fphar.2022.866625
80. Gao M, Zhang Z, Sun J, Li B, Li Y. The roles of circRNA-miRNA-mRNA networks in the development and treatment of osteoporosis. Front Endocrinol (Lausanne). 2022;13:945310. doi: 10.3389/fendo.2022.945310
81. Gao Z, Chen Z, Xiong Z, Liu X. Ferroptosis – A new target of osteoporosis. Exp Gerontol. 2022;165:111836. doi: 10.1016/j.exger.2022.111836
82. He X, Wang Y, Liu Z, Weng Y, Chen S, Pan Q, et al. Osteoporosis treatment using stem cell-derived exosomes: A systematic review and meta-analysis of preclinical studies. Stem Cell Res Ther. 2023;14(1):72. doi: 10.1186/s13287-023-03317-4
Review
For citations:
Toroptsova N.V., Nikitinskaya O.A., Nasonov E.L. To the 100th anniversary of the birth of academician V.A. Nasonova. Osteoporosis: Yesterday, today, tomorrow. Rheumatology Science and Practice. 2023;61(3):249-259. (In Russ.) https://doi.org/10.47360/1995-4484-2023-249-259
Views:
495
Email this article 